Key result
Chondroitin sulfate reduces stroke lesion volume ~36% in fibrin-rich, but not platelet-rich, thrombi.
Why the study?
Does intravenous chondroitin sulfate reduce lesion volume and improve reperfusion in mouse models of ischemic stroke?
Does intravenous chondroitin sulfate reduce lesion volume and improve reperfusion in mouse models of ischemic stroke?
Answers are grounded in this paper and cite their sources.
Chondroitin sulfate reduces lesion volume and improves reperfusion in fibrin-rich stroke models by neutralizing histone-mediated prothrombotic effects, offering a potential alternative to rtPA.
BACKGROUND: Ischemic stroke requires effective reperfusion therapies to limit brain injury, yet rtPA (recombinant tissue-type plasminogen activator) efficacy is limited, particularly in platelet-rich thrombi. Neutrophil extracellular traps (NETs) and their components, especially histones and DNA, contribute to thrombolysis resistance. Chondroitin sulfate (CS), a glycosaminoglycan with high affinity for extracellular histones, may neutralize their prothrombotic effects and improve outcomes. This study aimed to evaluate the effects of CS in preclinical ischemic stroke models and its impact on components of neutrophil extracellular traps. METHODS: Two mouse models of middle cerebral artery occlusion were used: a fibrin-rich thromboembolic stroke model (rtPA-sensitive) and a platelet-rich aluminum chloride model (rtPA-resistant). Mice received intravenous CS (30-120 mg/kg), rtPA (10 mg/kg), or a combination of both. Lesion volume, tissue recanalization/reperfusion, hemorrhagic transformation, and functional connectivity were assessed via 7T magnetic resonance imaging and ultrafast Doppler imaging. In vitro coagulation-fibrinolysis assays examined the effects of neutrophil extracellular trap components on fibrin polymerization and fibrinolysis, and their modulation by CS±rtPA. RESULTS: In the fibrin-rich model, CS alone reduced lesion volume by 36% and improved recanalization, comparable to rtPA (43%), without increasing hemorrhagic transformation. CS enhanced functional connectivity recovery at 24 hours, whereas combined CS+rtPA lost these benefits. In the platelet-rich model, CS did not affect lesion size, recanalization, or hemorrhage. In vitro, histones promoted clot stabilization and altered fibrinolysis, effects fully neutralized by equimolar CS in the absence of rtPA. With rtPA, CS's neutralizing capacity was reduced, and histone-driven profibrinolysis was accentuated at higher CS doses. DNA produced opposite effects to histones, and combined DNA+histones masked histone activity, resisting inhibition by CS+DNase. CONCLUSIONS: CS mitigates histone-mediated prothrombotic effects, improves reperfusion and network recovery in fibrin-rich stroke, but loses efficacy in platelet-rich thrombi and when combined with rtPA. These findings support CS as a potential adjunct or alternative therapy, particularly for patients with contraindications to rtPA.
No takes yet. Share an insight, caveat, or question.
Biatougou et al. (2025) studied Ischemic stroke. Chondroitin sulfate vs. rtPA (10 mg/kg) or combination was evaluated on Lesion volume. In a fibrin-rich mouse stroke model, chondroitin sulfate reduced lesion volume by 36% and improved recanalization, but lost efficacy in platelet-rich thrombi or when combined with rtPA.
Synapse has enriched 10 related papers. Consider them for comparative context: